LogicBio Therapeutics (OTCMKTS:LOGC) Posts Earnings Results, Misses Expectations By $0.25 EPS

LogicBio Therapeutics (OTCMKTS:LOGC) announced its earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.25), Zacks reports. The business had revenue of $32.20 million for the quarter, compared to the consensus estimate of $23.31 million.

LogicBio Therapeutics Stock Down 1.8%

LOGC opened at $13.75 on Wednesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The business has a 50 day moving average price of $14.80 and a 200 day moving average price of $10.40. The firm has a market cap of $628.88 million, a P/E ratio of -18.84 and a beta of 2.11. LogicBio Therapeutics has a twelve month low of $7.05 and a twelve month high of $15.60.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc. was a biotechnology company focused on developing genomic medicines for rare diseases, particularly conditions affecting children. Its research centered on approaches intended to address the underlying genetic causes of disease. The company developed GeneRide, a genome-editing platform designed to integrate therapeutic genetic material into a patient’s DNA. Its lead program, LB-001, was investigated for methylmalonic acidemia, a rare inherited metabolic disorder. LogicBio also worked on sAAVy, a platform for discovering and developing adeno-associated virus vectors for gene delivery.